naa a22 4500 510763871 CHVBK 20180411083149.0 cr unu---uuuuu 180411e20131001xx s 000 0 eng 10.1007/s12094-013-1014-4 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1014-4 Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer [Elektronische Daten] [S. Wang, Q. Li, K. Wang, Y. Dai, J. Yang, S. Xue, F. Han, Q. Zhang, J. Liu, W. Wu] Purpose: MicroRNA-31 (miR-31) has different expression patterns in various human cancers. Especially in urothelial carcinoma of the bladder, it has been demonstrated to be decreased expression in the invasive tumors and homozygously deleted. However, its clinical significance in human bladder cancer has not yet been elucidated. Thus, the purpose of this study was to investigate the diagnostic and prognostic values of miR-31 in this disease. Methods: Expression levels of miR-31 in 126 pairs of bladder cancer and adjacent normal tissues were detected by real-time quantitative RT-PCR assay. To determine its prognostic value, overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis. Results: MiR-31 expression in bladder cancer tissues was significantly lower than those in adjacent normal tissues (mean expression level: 2.1±0.9 vs. 3.8±1.2, P<0.001). When categorized into low vs. high expression, low miR-31 expression was negatively associated with the tumor stage (P=0.02), the status of recurrence (P=0.01), progression (P=0.01), and death (P=0.006) of patients with bladder cancer. Moreover, low miR-31 expression clearly predicted poorer PFS (P=0.001) and OS (P<0.001). In the multivariate analysis, low miR-31 expression was an independent prognostic factor for both PFS (P=0.01) and OS (P=0.008). Conclusion: These findings show that miR-31 may contribute to the progression of bladder cancer and its downregulation may be independently associated with unfavorable PFS and OS, suggesting that miR-31 might be a promising marker for further risk stratification in the treatment of this cancer. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Bladder cancer nationallicence MicroRNA-31 nationallicence Clinicopathological characteristics nationallicence Prognosis nationallicence Wang S. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut Li Q. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut Wang K. Department of Pathophysiology, Xiangya School of Medicine, Central South University, 410078, Changsha, Hunan, China aut Dai Y. Department of Geriatric Surgery, Xiangya Hospital, Central South University, 410008, Changsha, China aut Yang J. Department of Urology, The Third Xiangya Hospital of Central South University, 410013, Changsha, China aut Xue S. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut Han F. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut Zhang Q. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut Liu J. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut Wu W. Department of Geriatric Surgery, Xiangya Hospital, Central South University, 410008, Changsha, China aut Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 849-854 1699-048X 15:10<849 2013 15 12094 https://doi.org/10.1007/s12094-013-1014-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1014-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wang S. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut NATIONALLICENCE 700 1- Li Q. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut NATIONALLICENCE 700 1- Wang K. Department of Pathophysiology, Xiangya School of Medicine, Central South University, 410078, Changsha, Hunan, China aut NATIONALLICENCE 700 1- Dai Y. Department of Geriatric Surgery, Xiangya Hospital, Central South University, 410008, Changsha, China aut NATIONALLICENCE 700 1- Yang J. Department of Urology, The Third Xiangya Hospital of Central South University, 410013, Changsha, China aut NATIONALLICENCE 700 1- Xue S. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut NATIONALLICENCE 700 1- Han F. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut NATIONALLICENCE 700 1- Zhang Q. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut NATIONALLICENCE 700 1- Liu J. Department of Urology, The First Affiliated Hospital, Bengbu Medical College, 233030, Bengbu, China aut NATIONALLICENCE 700 1- Wu W. Department of Geriatric Surgery, Xiangya Hospital, Central South University, 410008, Changsha, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/10(2013-10-01), 849-854 1699-048X 15:10<849 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer